Checkpoint inhibition for treating Hodgkin and Non-Hodgkin lymphoma in the context of allogeneic stem cell transplantation: A survey-based registry study of the EBMT Lymphoma Working Party.

Hodgkin’s Disease (HD)

Non-Hodgkin’s Lymphoma (NHL)

This study aims to investigate safety and efficacy of immune checkpoint inhibitor treatment before and after allogeneic stem cell transplantation in NHL and HL. Main objectives of the study are to investigate if: checkpoint blockade pre-treatment might influence the outcome of a subsequent allo-HSCT post-transplant checkpoin

Patients who received an allo-HSCT after January 2014 Documented pre or post-transplant exposure to Immune checkpoint inhibitors Diagnosis of NHL or HL Age over 18 years at transplant Donor: SIB, UD, haplo-identical donor, cord blood donor Any conditioning regimen